联科生物明星产品:固定破膜剂Fix&Perm

  • Post category:产品通讯
  • Post views:2341 次访问

联科生物明星产品:固定破膜剂Fix&Perm

联科生物固定破膜剂(Fix&Perm)质量优秀,操作简单,深受广大科研人员好评与喜爱,具有以下三大优点:

  1. 破膜后细胞分群保持完好
  2. 溶血、破膜、染色一步完成,节约成本,操作简便
  3. 保持抗体的特异性、灵敏度以及可重复性

联科生物固定破膜剂产品

引用联科固定破膜剂部分参考文献:
[1] Yin Q, Shen J, Chen L, et al. Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly (β-amino esters)[J]. Biomaterials, 2012, 33(27): 6495-6506.. (IF: 8.55)

[2] Yin Q, Zhang Z, et al. Multifunctional nanoparticles improve therapeutic effect for breast cancer by simultaneously antagonizing multiple mechanisms of multidrug resistance[J]. Biomacromolecules, 2013, 14(7): 2242-2252.(IF:5.75)

[3] Yang Y, Gao Y, Chen L, et al. Downregulation of survivin expression and enhanced chemosensitivity of MCF-7 cells to adriamycin by PDMAE/survivin shRNA complex nanoparticles[J]. International journal of pharmaceutics, 2011, 405(1): 188-195. (IF:3.65)

[4] Yuan C, Zhang H, Wang W, et al. Transmembrane protein 63A is a partner protein of Haemonchus contortus galectin in the regulation of goat peripheral blood mononuclear cells[J]. Parasites & vectors, 2015, 8(1): 211. (IF:3.43)

[5] Yan L, Xie K M, Yang G Q, et al. GCS induces multidrug resistance by regulating apoptosis-related genes in K562/AO2 cell line.[J]. Cancer Chemotherapy & Pharmacology, 2009, 66(3):433-439.(IF: 2.76)

[6] Zhang H X, Zhu B, Fu X X, et al. BTLA associates with increased Foxp3 expression in CD4+ T cells in dextran sulfate sodium-induced colitis[J]. International journal of clinical and experimental pathology, 2015, 8(2): 1259. (IF: 1.89)

[7] Zhang Q, Deng C, Rao F, et al. Silencing of desmoplakin decreases connexin43/Nav1. 5 expression and sodium current in HL 1 cardiomyocytes[J]. Molecular medicine reports, 2013, 8(3): 780-786. (IF: 1.55)

[8] Li X, Wang Y, Han C, et al. Colorectal cancer progression is associated with accumulation of Th17 lymphocytes in tumor tissues and increased serum levels of interleukin-6[J]. The Tohoku journal of experimental medicine, 2014, 233(3): 175-182. (IF: 1.35)